{"id":"W2038906686","doi":"10.1002/ajh.23408","title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors","year":2013,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ariad Pharmaceuticals; Teva Pharmaceutical Industries; Pfizer","keywords":"Medicine; Internal medicine; Gastroenterology; Neutropenia; Adverse effect; Dasatinib; Myeloid leukemia; Rash; Phases of clinical research; Imatinib; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003417694,0.0004739312,0.002485286,0.0006588562,0.00007824702,0.00001082373,0.0003640396,0.0001078374,0.0002945065],"category_scores_gemma":[0.000480758,0.000340581,0.0003234699,0.0007127643,0.00037426,0.0001382774,0.0001062795,0.0003559837,0.00001299547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002757981,"about_ca_system_score_gemma":0.002203312,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007653378,"about_ca_topic_score_gemma":0.0002121841,"domain_scores_codex":[0.9956839,0.0001989131,0.002336073,0.0004555591,0.0006396351,0.0006859232],"domain_scores_gemma":[0.9948005,0.000413996,0.002384063,0.0006667146,0.001223952,0.0005107729],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.105464,0.05411507,0.01012668,0.002982555,0.005764986,0.006311873,0.008727133,0.0004289898,0.3221535,0.000122782,0.009087805,0.4747146],"study_design_scores_gemma":[0.1916423,0.5818952,0.002428598,0.001795102,0.002026487,0.005376761,0.004238569,0.0009067371,0.2067118,0.00004342105,0.002167924,0.0007671683],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952301,0.001132921,0.0002256337,0.0005017992,0.000280531,0.002525713,0.000057971,0.00001964111,0.00002562795],"genre_scores_gemma":[0.9974998,0.0001013044,0.001827578,0.0001062468,0.0001674621,0.0001012405,0.00002329654,0.00007869499,0.00009437575],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5277801,"threshold_uncertainty_score":0.9999046,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01233807531413088,"score_gpt":0.3062197094384318,"score_spread":0.2938816341243009,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}